Osteonecrosis in Children With Acute Lymphoblastic Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-07-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute lymphoblastic leukemia is the most common form of childhood cancer with current treatment survival rates approaching 80%. Improved outcomes show an increased number of survivors at risk for long-term treatment related side effects including osteonecrosis. Osteonecrosis, or bone death, is caused by blood supply loss to the bone causing pain and poor quality of life. The hips, shoulders, knees and ankles may be affected. Pain is the usual presenting symptom and may become severe requiring surgical decompression or replacement of the affected joint. Long-term effects including arthritis and progressive joint difficulties will not be known for decades. This study aims to determine the risk factors for developing osteonecrosis that will lead to information for earlier detection and prevention. The study will be the basis for future intervention and prevention trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Osteoporosis in Children With ALL

NCT00330538

Leukemia, Lymphocytic, Acute, L1

COMPLETED

A Study of Actonel for the Prevention of Bone Loss

NCT00452439

Leukemia Lymphoma

COMPLETED PHASE3

Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study

NCT02632903

Osteoporosis Osteonecrosis Acute Lymphoblastic Leukemia

WITHDRAWN PHASE2

Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study

NCT01663129

Acute Lymphoblastic Leukemia Nephrotic Syndrome Rheumatism

COMPLETED

A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors

NCT00186901

Leukemia, Lymphoblastic, Acute Osteoporosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteonecrosis Acute Lymphoblastic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Enrollment in the STOPP-CIS study
* Informed consent of patient or care givers
* \>5 years of age at MRI assessment

Exclusion Criteria

* Individuals with a history of claustrophobia precluding MRI assessment

Minimum Eligible Age

5 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Childrens Hospital of Eastern Ontario

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jacqueline Halton

Role: PRINCIPAL_INVESTIGATOR

Childrens Hospital of Easten Ontario

Locations

Explore where the study is taking place and check the recruitment status at each participating site.